Abstract
There are no human cancer cell lines of external auditory canal origin available for research use. This report describes the establishment of a culture condition for external auditory canal squamous cell carcinoma, derived from human tumor tissue. Successive squamous cell carcinoma colonies were dissociated by trypsin, subcultured, and maintained on a feeder layer (MMC‐TIG‐1‐20), yielding a clonally proliferating cell culture. Two morphological types of colony were observed: (a) densely packed colonies and (b) colonies with indistinct boundaries characterized by cell–cell complexes with fibroblast feeder cells. The SCC‐like characteristics of these cells were evidenced by positivity for p53, SCCA1/2, cytokeratin, and vimentin, and cancer stem cell properties were indicated by positivity for CD44, CD133, Oct3/4, and alkaline phosphatase (ALP). One of the unique properties of cell cultures is their tendency to form steric colonies in vitro on feeder layer cells. In addition, in the presence of fresh macrophages, the cells very slowly transform to break away from colonies as free cells, a process that resembles the epidermal–mesenchymal transition, whereby cell–cell interactions are weakened and migration activity is enhanced. These factors are purported to play a key role in cancer cell metastasis.
Keywords: external auditory canal, primary cell culture, squamous cell carcinoma, stem cell, temporal bone
No human cancer cell lines of external auditory canal (EAC) origin are available for research use. This report describes the establishment of a culture condition for EAC squamous cell carcinoma (SCC). These cell cultures had cancer stem cell properties and tended to form steric colonies on feeder cells. These cell cultures could be used in future research on EAC‐SCC.
Abbreviations
- EAC
external auditory canal
- FSP
fibroblast surface protein
- PBMC
Peripheral blood mononuclear cell
- PDC
poorly differentiated cluster
- SCC
squamous cell carcinoma
- STR
short tandem repeat
- VAF
variant allele frequency
Squamous cell carcinoma (SCC) of the external auditory canal (EAC‐SCC) is one of the rarest head and neck SCCs [1], with an estimated incidence of only 1 in 1 million [2]. The prognosis of advanced‐stage EAC‐SCC, in particular, remains poor, despite near‐daily progress in diagnostic imaging and treatment strategies for head and neck cancers.
Cell lines, which are used for the elucidation of carcinogenic mechanisms and efficacy tests for therapeutic drugs [3], are a very powerful tool in cancer research. Several cell lines have helped clinicians to collect evidence for the diagnosis and treatment of head and neck cancers (e.g., Hep‐2 [laryngeal carcinoma] [4], Ca9‐22 [oral carcinoma] [5], and SAS [tongue carcinoma] [6]). However, no such cell line has been established for EAC‐SCC. The establishment of an EAC‐SCC cell line is an essential first step in the construction of a human chimeric mouse model. This is one reason why in vivo and in vitro research into the disease’s treatment has lagged behind other head and neck cancers, and why its outcomes have failed to improve.
Bryne et al. report, on their studies of squamous cell carcinoma of the head and neck, that the invasive ability, not the degree of differentiation of cancer cells, is an important factor for the assessment of clinical aggressiveness and prognosis [7, 8]. Grade or Score 4 infiltration patterns show a widespread cellular dissociation in small groups and/or in single cells. The concept of tumor budding, which is characterized by the presence of a single cell or tumor cluster of tumor cells (< 5 cells) at the invasive front, has been introduced as an evaluation standard of head and neck SCC [9]. Tumor budding has been evaluated only for tumor masses of < 5 cells, but there are clusters of 5 or more cancer cells at the invasive front. Poorly differentiated clusters (PDCs) are tumor stroma that are histologically defined as tumor cell clusters composed of five or more tumor cells and having no gland‐like structure. This PDC is a negative prognostic factor established in several types of cancer [10, 11, 12]. In addition, a high incidence of PDC is associated with poor prognosis and recurrence of liver, lung, lymph node/local recurrence, and peritoneal dissemination [10].
In the present study, we succeeded in culturing human‐derived EAC‐SCC cells. The established cell cultures harbored cells with two types of morphologies. Unlike normal SCC cells, our cell cultures form amorphous cell clusters only on feeder cells, not on the culture vessel surface. When the cell size reaches a certain level, some cells are dispersed around the host cluster and proliferate by creating satellite clusters. We hypothesize that cells with this morphology possess the characteristic properties of cancer stem cells, because they are derived from a deep tumor in a hypoxic environment [13] and express cancer stem cell markers [14, 15, 16, 17].
Materials and methods
Ethic statement
The Clinical Research Ethics Review Committee of Kyushu University Hospital approved the study (permit no. 30‐268). Written informed consent for the current research project was obtained before harvesting the tumor tissue and blood sample. This study was also conducted according to the principles of the Declaration of Helsinki.
Patients
Tumor tissue was collected for histological diagnoses. One patient (case 1) was a 69‐year‐old woman with well‐differentiated SCC of the left external auditory canal (clinical stage: cT3N1M0). The other patient (case 2) was a 71‐year‐old woman with well‐to‐moderately differentiated SCC of the right external auditory canal (clinical stage: cT4N0M0). These samples were used to create the cell cultures.
Growth medium
The growth medium consisted of Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Sigma‐Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS: Sigma‐Aldrich), 0.1 mm MEM nonessential amino acids solution (Thermo Fisher Scientific, Waltham, MA), 1 mm sodium pyruvate (Thermo Fisher Scientific), 2 mm L‐glutamine (Thermo Fisher Scientific), and 1% antibiotic‐antimycotic mixed stock solution (Nacalai Tesque, Inc., Kyoto, Japan).
Antibodies
Tables 1 and 2 shows the antibodies used for the cultured cells (Table 1) and paraffin‐embedded specimens (Table 2).
Table 1.
Antibodies for immunocytochemistry.
Antibody | Clone | Host | Dilution for ICC | Source |
---|---|---|---|---|
Primary antibodies | ||||
pan‐Cytokeratin‐Alexa 488 | C11 | Mouse | 1 : 50 | Santa Cruz Biotechnology, sc‐8018 AF488 |
Vimentin‐PE | V9 | Mouse | 1 : 50 | Santa Cruz Biotechnology, sc‐6260 PE |
p53‐Alexa 488 | 7F5 | Rabbit | 1 : 50 | Cell Signaling Biotechnology, #5429 |
CD44‐PE | IM7 | Rat | 1 : 50 | Tonbo biosciences, 50‐0441 |
CD133‐APC | AC133 | Mouse | 1 : 50 | Miltenyi Biotec, 130‐113‐106 |
SCCA1/2 | 4C8 | Mouse | 1 : 50 | LifeSpan BioSciences, LS‐C172653 |
Oct‐3/4 | C‐10 | Mouse | 1 : 50 | Santa Cruz Biotechnology, sc‐5279 |
Secondary antibody | ||||
Alexa Fluor® 555 anti‐mouse IgG | Goat | 1 : 1000 | Invitrogen, A21424 |
ICC, Immunocytochemistry.
Table 2.
Antibodies for immunohistochemistry.
Antibody | Clone | Host | Dilution for IHC | Source |
---|---|---|---|---|
Primary antibodies | ||||
p53(IgG) | DO‐7 | Mouse | 1 : 100 | Dako, M7001 |
SCCA1/2(IgG) | 4C8 | Mouse | 1 : 150 | LifeSpan BioSciences, LS‐C172653 |
CD44(IgG) | 2C5 | Mouse | 15 µg·mL−1 | R&D Systems, BBA10 |
Human fibroblast surface protein (IgM) | 1B10 | Mouse | 1 : 100 | Sigma‐Aldrich, F4771 |
Secondary antibodies | ||||
Biotinylated anti‐mouse IgG | Horse | 1 : 1000 | Vector Laboratories, BA‐2001 | |
Biotinylated anti‐mouse IgM | Goat | 1 : 1000 | Vector Laboratories, BA‐2020 |
IHC, Immunohistochemistry.
Cell lines
HeLa cells were obtained from the RIKEN BRC Cell Bank for use as the cytokeratin‐positive control in the immunostaining experiments; SCC‐9 cells were obtained from ATCC for use as the p53 and SCCA1/2‐positive control. Both lines were maintained in the growth medium at 37 °C with 5% CO2.
Primary human fibroblasts
Primary human fibroblasts were prepared from the primary culture of SCC with a 200 µL micropipette tip under a microscope. Collected cells were then cultured for use as the CD44‐ and vimentin‐positive control and as the p53‐, SCCA1/2‐, CD133‐, Oct3/4‐negative control in the immunostaining experiments.
Feeder culture (MMC‐treated TIG‐1‐20)
TIG‐1‐20 cells were obtained from the JCRB Cell Bank (National Institutes of Biomedical Innovation, Health and Nutrition). When the cells reached 80% confluence, they were treated with 10 µg·mL−1 of mitomycin C (MMC: FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) [18]. After 2.5‐h incubation, they were washed, disassociated by trypsin digestion, and seeded on a 60‐mmΦ dish (1.5 × 105 cells per dish).
Fresh human macrophages
Peripheral blood was obtained from a consenting healthy donor. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density centrifugation and seeded onto EAC‐SCC cell cultures at 1 × 106 cells·mL−1 (3 mL per 60 mmΦ dish). The EAC‐SCC cell cultures were maintained by changing the medium every 3 days after the addition of PBMCs (lymphocytes, monocytes, macrophages, and dendritic cells). Free‐cell components (lymphocytes and some dendritic cells) were removed by refreshing the culture medium. In addition, since T lymphocytes die very quickly in the absence of stimulation [19], macrophages and dendritic cells soon became the only PBMC‐derived cells in this mixed culture.
Immunofluorescence and alkaline phosphatase staining
Cell samples for immunostaining were prepared as follows. Single colonies from cell cultures were collected under a microscope and dispersed with trypsin. From this cell suspension, a single‐layer specimen of cells was prepared on a glass slide using Cytospin 4® (Thermo Fisher Scientific). A slide for the control cell samples, which included SCC9 cells and human fibroblasts for p53, SCC1/2, CD44, CD133, and Oct3/4 staining, were prepared with cytospin according to the protocol used for EAC‐SCC cells. Immediately after centrifugation, cells and fragments were fixed with methanol : acetone 1 : 1 (v/v) for 20 min at −20 °C. Hela cells and human fibroblasts for vimentin and cytokeratin staining were seeded on eight‐chamber slides and allowed to attach overnight. Cells were fixed with methanol : acetone 1 : 1 (v/v) for 20 min at −20 °C according to the protocol used for EAC‐SCC cells. These preparations for cytoplasmic antigen staining were additionally permeabilized with PBS containing 0.5% Triton X‐100 and 0.05% NaN3 for 10 min at room temperature.
Following fixation, for cell surface marker staining, preparations were incubated with anti‐CD44‐PE or anti‐CD133‐APC for 1 h at room temperature. For cytoplasmic marker staining, samples were incubated with anti‐pan‐Cytokeratin‐Alexa Fluor® 488 and Vimentin‐PE at room temperature for 1 h, and with anti‐p53‐Alexa Fluor® 488 and anti‐SCCA1/2 (mouse IgG) at 4 °C overnight.
For SCCA1/2 and Oct3/4 antigens, the samples were further stained with goat anti‐mouse IgG (H + L) highly cross‐adsorbed secondary antibody conjugated Alexa Fluor® 555 after the primary antibody reaction. Slides were then mounted with DAPI Fluoromount‐G® (SouthernBiotech, Birmingham, AL, USA) for nuclear staining. Unfixed cytospin preparations were tested with a Vector® Blue Alkaline Phosphatase Substrate kit (Vector Labs, Burlingame, CA, USA) to check for alkaline phosphatase (ALP) activity.
Immunohistochemistry
Immunohistochemistry was performed on formalin‐fixed, paraffin‐embedded specimens obtained from the EAC tumor samples. Briefly, paraffin sections were cut into 4‐µm‐thick slices with a microtome and mounted on adhesive glass slides (Matsunami Glass Ind., Ltd., Osaka, Japan). After deparaffinization and rehydration, sections were incubated with the primary antibody raised against p53, SCCA1/2, CD44, and fibroblast surface protein (FSP). For the negative control, PBS was substituted for the primary antibody according. After blocking endogenous peroxidase activity with 3% hydrogen peroxide and performing microwave antigen retrieval, the test samples were incubated with biotinylated horse anti‐mouse IgG or biotinylated goat anti‐mouse IgM antibody. Antibody binding was visualized with an avidin‐peroxidase (VECTASTAIN® Elite kit; VectorLabs, Burlingame, CA, USA) and 3,3′‐diaminobenzidine tetrahydrochloride substrate (Dojindo, Kumamoto, Japan). After staining, the slides were washed and dehydrated and coverslips were applied.
Short tandem repeat analysis
Genomic DNA was extracted from the cell cultures and the tumor samples from the patients using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA). The Gene Print PowerPlex 16HS System (Promega, Madison, WI, USA) was used to amplify the extracted DNA. The amplified fragments were detected using an Applied Biosystems 3500xL Genetic Analyzer (Thermo Fisher Scientific).
P53 DNA sequencing
Genomic DNA was extracted from the EAC‐SCC cell line using a DNeasy Blood & Tissue Kit (Qiagen, Valencia). The extraction of genomic DNA from the fresh‐frozen donor tumor tissues and the patient‐matched skin tissue was conducted using DNeasy Blood and Tissue Kits (Qiagen, Chatsworth, CA, USA). Subsequently, the extracted DNA samples were subjected to whole‐exome sequencing (WES) at the Beijing Genomics Institute (Shenzhen, China). Library preparation was conducted using an Agilent SureSelect All Exon V6 exome capture kit (Agilent Technologies, Santa Clara, CA, USA). The captured libraries were sequenced according to the manufacturer’s protocols using a DNBSEQ‐G400 High‐throughput Rapid Sequencing Set (MGI Tech, Shenzhen, China) with the paired‐end 100‐bp sequence read option. The sequence data were processed via the in‐house pipeline Genomon 2.5.2 (http://genomon.hgc.jp). Briefly, the sequencing reads were aligned to the NCBI Human Reference Genome, Build 37 hg19 with bwa version 0.7.8, using the default parameters (http://bio‐bwa.sourceforge.net/). PCR duplicate reads were removed using Picard (http://www.picard.sourceforge.net). Mutation calling was performed using the EBCall algorithm with the following parameters: (a) mapping quality score ≥ 30; (b) base quality score ≥ 15; (c) both tumor and normal depth ≥ 8; (d) variant reads in tumors ≥ 4; (e) variant allele frequency (VAF) in the tumor samples ≥ 0.05; (f) VAF in the normal samples < 0.1; (g) negative logarithm of the P‐value from Fisher’s exact test ≥ 1.3; and (h) negative logarithm of the P‐value for EBCall ≥ 5. The mutations in TP53 were visualized using the Integrated Genomic Viewer (IGV, https://software.broadinstitute.org/software/igv/).
Image capture
Representative culture fields were imaged with the OLYMPUS DP2‐BSW software program using a CCD camera (OLYMPUS DP72) connected to a microscope (OLYMPUS BX51).
Results
Preparation of primary tissue culture
Tumor biopsy samples were surgically resected and sterilized by soaking in 99% ethanol for a few seconds to prevent microbial contamination. Thereafter, the tissue was quickly transferred to a sterile container filled with a PBS(−), brought to a clean workbench, and washed with Dulbecco’s PBS (PBS(−): FUJIFILM Wako Pure Chemical Corporation) four times. Connective tissue, adipose tissue, and blood vessels were removed by forceps while in the growth medium. The resulting fragments were placed on a gelatin‐coated 60 mmΦ dish, and pressed‐down with a thick cover glass (Fig. 1). Placing the cover glass on the tissue fragments ensures that they come into contact with the culture surface. As a result, the cells are more reliably extended from the tissue fragment to the culture surface.
Fig. 1.
Isolation protocol of SCC‐enriched tissue fragments. Connective tissue, adipose tissue, and blood vessels were removed from the sterilized tumor sample while in the growth medium. The fragments of tumor tissue were placed on a gelatin‐coated 60 mmΦ dish and were pressed‐down with a thick cover glass to keep the tissue from floating. These tissues were cultured in the growth medium until squamous cells and/or cell clusters appeared from the tissue fragments.
Human‐derived EAC‐SCC cell culture
As shown in Fig. 2, several types of cells infiltrated from the cancer tissue fragments and spread on the culture surface to form a colony within several weeks after the start of the culture. In the culture shown in Fig. 2A, highly differentiated squamous epithelium‐like cells (circled in red) were attached to the culture vessel surface (Type‐1 colony). In the culture shown in Fig. 2B, fibroblasts (circled in yellow) exuding from a cancer tissue fragment spread on the surface of the culture vessel. The exuded cancer cells formed an amorphous cell mass (circled in green) (Type‐2 colony) on these fibroblasts. In the culture shown in Fig. 2C, amorphous cancer cell clumps were seen in the cultures on the differentiated squamous epithelial cells instead of the fibroblasts seen in the culture shown in Fig. 2B. In the culture shown in Fig. 2D, multiple types of cells were seeping out from the cancer tissue fragments. In this culture, cells with an epithelial cell‐like morphology (cobblestone‐like uniform sheet) were observed, and this was not seen in other cultures. Colony cells with a unique shape in cultures were picked up with a micropipette tip under a microscope, dispersed by trypsin digestion, and transferred to an MMC‐TIG‐1‐20 feeder culture. Culturing was then continued. As a result, it was possible to continuously culture only the squamous cell carcinoma cells that formed an amorphous cell mass (Fig. 2B–D). Cell cultures from both patients exhibited similar phenotypes. The cells from both patients had a very slow growth rate and a passage rate of once every 4 weeks. This culture was maintained for more than 1 year and was used for subsequent experiments. The differentiated squamous cell carcinoma cells (Fig. 2A,D) and the epithelial cell‐like cancer cells (Fig. 2C) disappeared from the culture during passaging. The fibroblast cells shown in Fig. 2B,C were grown without feeder cells, frozen in liquid N2, and used for subsequent experiments. Repeated passaging yielded a cell culture in which two types of homogeneous colonies were reliably and reproducibly formed (Fig. 3). Type A colonies are densely packed and occupy a large proportion of all colonies. Type B colonies have indistinct boundaries characterized by cell–cell complexes with TIG‐1‐20 fibroblast feeder cells.
Fig. 2.
Primary SCC tissue culture. (A) Type‐1 colony: very differentiated squamous carcinoma cells (red circle) leaked from the cancer tissue fragment and spread on the surface of the culture vessel. Scale bar, 50 µm. (B) Type‐2 colony: squamous cell carcinoma cells (green circle) leached out of the cancer tissue fragments as cell clusters, and began to grow on the fibroblasts (yellow circle) instead of the culture surface. Scale bar, 50 µm. (C) Type‐3 colony: highly differentiated squamous cell carcinoma cells (red circle) adhered to the culture vessel surface, and the squamous cell carcinoma clusters (green circle) shown in (B) and (C) adhered and proliferated on those cells. Scale bar, 50 µm. (D) Mixed type culture: epithelial cell‐like squamous cells (blue circle) and fibroblasts (yellow circle) leaked from the same cancer fragments and spread on the surface of the culture vessel. As mentioned in (B), squamous cell carcinoma cell clusters (green circle) were attached and proliferated on fibroblasts. Scale bar, 50 µm.
Fig. 3.
Passaging maintained human‐derived EAC‐SCC colonies in feeder culture. SCC colonies were microscopically picked up from the SCC‐feeder cell culture, dispersed with trypsin, and then spread on feeder cells. During culturing, two distinct types of colonies grew: Type‐A colonies, which were densely packed and which accounted for a large number of the colonies overall, and Type‐B colonies, which formed cell complexes with feeder cells and which were a relatively minor population. Scale bar in both panels of upper row and left panel of lower row, 50 µm. Scale bar in right panel of lower row, 100 µm.
Cancer cell markers of tissue specimens
Histological specimens from the original donor were examined to investigate the distribution of cells positive for p53, SCCA1/2 [20], CD44, and FSP [21]. p53‐positive cells were mainly localized to the outer shell of the tumor lobe. In contrast, SCCA1/2‐ and CD44‐positive cells were preferentially located in the tumor core. Fibroblasts were mainly distributed around the tumor lobe (Fig. 4).
Fig. 4.
Immunohistochemical staining of squamous cell carcinoma tissue of the external ear canal. Histological specimens from the original donor were stained with p53, SCCA1/2, CD44, and FSP. p53‐positive cells, and SCCA1/2‐ and CD44‐positive cells were localized to the outer shell of the tumor lobe and tumor core, respectively. Fibroblasts were mainly distributed around the tumor lobe. Scale bar, 50 µm.
Somatic mutations of TP53 are the most frequent driver mutations in head and neck squamous cell carcinoma [22]. Therefore, to explore whether the donor EAC‐SCC tumor tissues harbored somatic mutations of TP53, and whether the established cell culture retained identical alterations, we performed WES on genomic DNA derived from the cell culture and the donor tumor tissue (from case 2) and used a patient‐matched skin tissue sample as a noncancerous control. WES and the subsequent bioinformatics analysis revealed that both the cell line and the donor tumor tissues had a nonsynonymous mutation in exon 7 of TP53 (TP53G245S), which is reportedly a hotspot mutation in TP53 (variant allele frequency: 8.3% and 49.3% in the donor tumor tissue and the cell culture, respectively) [23]. Thus, the established cell culture had retained the important genetic alteration of the donor EAC‐SCC (Fig. S1).
Cancer cell markers in human‐derived SCC cells
Double immunostaining experiments for cytokeratin–vimentin and p53–SCCA1/2 were performed to verify that these cells were SCC cells derived from the donor tumor tissue. Immunocyto‐staining revealed that the cells were double‐positive for both cytokeratin and vimentin showed, suggesting the possibility of malignancy [24, 25, 26] (Figs 5 and 6). In order to examine the stemness of these cells, colonies of these cells were excised under a microscope and dispersed by trypsin/EDTA treatment, and the presence of cancer stem cell markers (CD44 [14, 16, 17], CD133 [14, 15, 16, 17], Oct3/4 [14, 18], ALP [16]) was examined in these free cells. The EAC‐SCC cells were found to be positive for these cancer cell markers (Fig. 7).
Fig. 5.
Fluorescence immunostaining with anti‐cytokeratin‐Alexa 488 (green) and anti‐vimentin‐PE (red). EAC‐SCC cells were positive for both anti‐pan‐Cytokeratin‐Alexa 488 (green) and anti‐Vimentin‐PE (red). Cytokeratin and vimentin were located in the cytoplasm but not in the nuclei. Human fibroblasts were positive for anti‐Vimentin‐PE (red), but negative for anti‐pan‐Cytokeratin‐Alexa 488 (green). Hela cells were positive for anti‐pan‐Cytokeratin‐Alexa 488 (green) but not anti‐Vimentin‐PE (red). Scale bar, 50 µm.
Fig. 6.
Fluorescence immunostaining with cancer‐specific antibodies. Cells were prepared on slides using Cytospin 4® (Thermo Fisher Scientific). The cells were double‐stained with anti‐p53‐Alexa 488 (green) and anti‐SCCA1/2 + Alexa Fluor® 555 anti‐mouse IgG (red). Our cells were double‐positive for p53 and SCC. On the other hand, human fibroblast cells were negative for both anti‐p53‐Alexa 488 (green) and anti‐SCCA1/2 + Alexa Fluor® 555 anti‐mouse IgG (red). Scale bar, 50 µm.
Fig. 7.
Examination of cancer stem cell markers in EAC‐SCC cells. Cells were prepared on slides using Cytospin 4® (Thermo Fisher Scientific). EAC‐SCC cells were tested with anti‐CD44‐PE, anti‐CD133‐APC, and anti‐Oct‐3 / 4 + Alexa Fluor® 555 anti‐mouse IgG. DAPI (blue) was used to identify the location of cell nuclei for immunofluorescence staining. Fibroblasts were positive for CD44 and were not stained with CD133 or Oct3/4. In addition, ALP activity was observed in our EAC‐SCC cells but not in fibroblasts. Scale bar, 50 µm.
Macrophages disperse EAC‐SCC colonies
External auditory canal cancer has an extremely poor prognosis, often involving metastatic infiltration from the primary focus into the surrounding tissue and accompanying inflammation. Therefore, to test how EAC‐SCC colonies behave in the presence of inflammatory cells, the EAC‐SCC cell–feeder culture was monitored for changes after adding human macrophages.
First, colonies were scraped from the EAC‐SCC cell–feeder culture by micropipette tip under microscope, then seeded on a feeder culture. Once the adherence of the new colonies to the medium and growth was confirmed, fresh macrophages were layered on the culture (Fig. 8A: EAC‐SCC with macrophage and 8B: EAC‐SCC cell without macrophage). On day 3, macrophages had bound to many cells, including EAC‐SCC cell–fibroblast complexes, and started to penetrate inside the clusters (Fig. 8C,D). On day 10, EAC‐SCC cells had started to disperse from colonies, migrating over the surrounding feeder cells (Fig. 8E). While this trend was similar to the cells’ normal proliferative behavior (Figs 3 and 8F,H), one key difference was that they did not form exclusive colonies consisting only of EAC‐SCC cells. However, they did form steric complexes with some of the healthier feeder cells (Fig. 8G‐1). Fibroblast‐bound cells ranged from 5 to 20 µm in size. Trypan blue dye exclusion tests were performed to confirm that these cells were not macrophages: While smaller (< 5 µm) cells were dyed blue, none of the > 20‐µm cells were dyed blue (Fig. 8G‐2). This suggests that the cells of least 20 µm in size within the complexes were EAC‐SCC cells.
Fig. 8.
Transformation of explosively spreading colonies of human‐derived SCC cells. (A, B) Peripheral blood mononuclear cells (PBMCs) were plated on day 1 over colonies of our cells. Free cells were discarded when the culture medium was replaced every three days. The cultures were maintained for one month. (C) Macrophage had bounded to many cells, including EAC‐SCC cell–fibroblast complexes on day 3. (D) Some cancer cells migrated from the colony. (E, F) By day 10 after culture initiation, lymphoid cells disappeared from the culture, and only macrophages remained as cells derived from PBMCs. (G, H) EAC‐SCC cells co‐cultured with macrophages did not form exclusive colonies consisting only of EAC‐SCC cells and formed steric complexes with some of the healthier feeder cells. EAC‐SCC cells without macrophage kept to form the colony. Green arrows show migrated cancer cells. (A–F), (G‐1), (H): ×100. (G‐2): ×200 Scale bar, 50 µm.
In normal cultures without macrophages, some cells broke away from the EAC‐SCC colonies (Fig. 8D), forming new ones and proliferating in a distant area (Fig. 8H). This phenomenon had the appearance of normal proliferation, but the cells did not disperse and proliferate as they did in the EAC‐SCC cell–macrophage cultures.
Short tandem repeat analysis
The cell colonies from case 1 were too small to extract sufficient DNA for analysis. The doubling time of the cells derived from case 1 was slower than that of the cells derived from case 2. Additionally, the cells derived from case 2 formed larger colonies than those of case 1. We were thus able to extract sufficient DNA from the cells cultured from case 2. The short tandem repeat (STR) profile of the cell culture did not match that of the host tumor sample exactly, but the STR similarity between the cell culture and host tumor sample was 0.96, which was sufficiently high that the STR profile of the cell culture could be considered the same as that of the host tumor sample. We, therefore, consider these cells to be an identical cell strain. In addition, we confirmed that there were no other identical cell lines in the Japanese Collection of Research Bioresources (JCRB; Table S1).
Discussion
In the present study, we successfully cultured human EAC‐SCC cells. These cell cultures have several unique characteristics (Table 3):
-
1
Colony formation with a steric structure characterized by cell–cell complexes with MMC‐treated TIG‐1‐20 fibroblasts
-
2
Very slow growth
-
3
Double positivity for SCCA 1/2 and p53 antigens, hallmarks of SCC
-
4
Positivity for several cancer stem cell markers (CD44, CD133, Oct3/4, ALP)
-
5
Double positivity for cytokeratin and vimentin
Table 3.
Characteristics of human derived EAC‐SCC cells.
Cell features | |
---|---|
Colony formation |
|
Growth rate | Very slow |
Immunohistochemistry | |
SCC markers | p53, SCC |
Cancer stem cell markers | CD44, CD133, Oct3/4, ALP |
Diagnosis and prognosis prediction | Double positivity for cytokeratin and vimentin |
This evidence supports the conclusion that the established cell culture did originate from SCC cells in the EAC, and that it possesses many of the characteristics of cancer stem cells. One of the stem cell markers, ALP, is a membrane‐bound enzyme. Four isoenzymes have been found in various tissues: intestinal ALP, placental ALP, germ‐cell ALP, and tissue‐nonspecific ALP. High levels of ALP have been reported to be a tumor marker for various cancers [27]. Many types of pluripotent stem cells, as well as iPS cells, are known to have ALP activity [28, 29, 30]. Expression of cancer stem cell markers, including CD44, CD133, Oct3/4, and ALP activity, may be one reason the growth of our cell cultures was suppressed. Furthermore, in addition to cytokeratin, our cell cultures were positive for vimentin, a marker of a poor prognosis in head and neck cancer [24, 25, 26].
Derived from an EAC‐SCC tumor, our cells formed steric colonies on the fibroblast feeder layer culture, but never on the surface of the culture vessel. One possible reason for the difficulty in creating sustainable in vitro cultures of EAC carcinomas is their difficulty in adhering to the culture vessel; successful cultures seem to require a scaffold of fibroblast feeder cells.
Since our cells were positive for cancer stem cell markers [14, 15, 16, 17], one might assume they are preferentially found in the interior of tumor lobes (a hypoxic environment) in vivo [31]. Unusually, immunostaining found that most of the p53‐positive cells were located on the exterior of the tumor lobe. Given its role in cell division, the p53 expression level within tumor masses (where cell cycle arrest is maintained by the hypoxic environment) is low. However, it seems reasonable to assume that the process would restart, and that the cells would start to proliferate, once brought into in vitro conditions with sufficient oxygen, at which point they would be p53‐positive. These histological findings strongly suggest that our cells originate from cancer cells in the tumor interior, a hypothesized cancer stem cell niche [31].
In vitro, the EAC‐SCC cells formed steric structure colonies on the feeder layer culture. We performed immunostaining of donor tumor tissue with an FSP antibody to further investigate this phenomenon. Fibroblasts were primarily located at the periphery of the tumor tissue, although a small number were present in the interior, suggesting that fibroblasts possess cadherins or other cell adhesion molecules with affinity for our cells, which mediate the latter’s maintenance and growth.
In the clinical setting, vimentin positivity is considered to be indicative of a poor prognosis [24, 25, 26]. SCC cells are known to express this molecule and exhibit enhanced migration potential as they transform into mesenchymal stem cells, a process known as the epithelial–mesenchymal transition [32]. Our cell cultures exhibit both of these properties.
PDC has been reported as a negative prognostic factor, which is established in several types of cancer [10, 11, 12]. EAC‐SCC cells form an amorphous cluster with feeder layer cells and/or with the same cells. Also, when proliferating, cells migrating from the cluster create satellites around this cluster and increase. This growth pattern appears to be a potential homolog of PDC seen in the invasive front of tumor budding in vivo. In addition, when co‐cultured with human macrophages derived from peripheral blood for long periods, the EAC‐SCC cell–fibroblast complexes slowly change to facilitate break‐away and dispersal. We presume that macrophages probably play some role in the human‐derived SCC colony dissociation. Thus, we propose our cell cultures as a potential ‘key cell’ in research to explore how changes in the tissue microenvironment caused by macrophage invasion, a trigger for inflammation, affect how SCC metastasizes and spreads.
Conclusion
In this study, we established and maintained cell cultures from human EAC‐SCC, and unlike normal SCC cells, these formed amorphous cell clusters only on feeder cells, not on the culture vessel surface. Our cell cultures possess many of the characteristics of cancer stem cells. These cell cultures could thus be used in future research on EAC‐SCC.
Conflict of interest
The authors report no personal financial support for this article and no conflicts of interest regarding any of the materials or devices described in this article.
Author contributions
NK involved in conceptualization. YS, AI, and MO performed the formal analysis. NK and TN contributed to funding acquisition. HO and TN performed the investigation, validation, and project administration. YS, AI, MO, AF, and TH involved in resources. NK supervised the article. YS, AI, and NK wrote original draft. YS, AI, NK, SM, AF, KK, KS, and RU reviewed and edited the manuscript.
Supporting information
Fig. S1. P53 sequencing analysis in human‐derived SCC. Somatic mutation in exon 7 of TP53 (TP53G245S), visualized using the Integrated Genomic Viewer (IGV). The sequencing coverage, reads, and altered bases in skin tissue (top), donor tumor tissues (middle), and the cell line (bottom) are shown.
Table S1. Short tandem repeat (STR) profiles.
Acknowledgements
The authors would like to thank Japan Medical Communication and Uni‐edit for editing our manuscript. Part of this work was supported by JSPS KAKENHI Grant Number JP 18H02951 and 18K16895.
Yuki Sekino, Akira Imaizumi and Noritaka Komune contributed equally to this work
Data accessibility
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
References
- 1. Kuhel WI, Hume CR and Selesnick SH (1996) Cancer of the external auditory canal and temporal bone. Otolaryngol Clin North Am 29, 827–852. [PubMed] [Google Scholar]
- 2. Barrs DM (2001) Temporal bone carcinoma. Otolaryngol Clin North Am 34, 1197–1218. [DOI] [PubMed] [Google Scholar]
- 3. Wilding JL and Bodmer WF (2014) Cancer cell lines for drug discovery and development. Cancer Res 74, 2377–2384. 10.1158/0008-5472.can-13-2971 [DOI] [PubMed] [Google Scholar]
- 4. Morris JC and Wildner O (2000) Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV‐tk. Mol Ther 1, 56–62. [DOI] [PubMed] [Google Scholar]
- 5. Ketabat F, Pundir M, Mohabatpour F, Lobanova L, Koutsopoulos S, Hadjiiski L, Chen X, Papagerakis P and Papagerakis S (2019) Controlled drug delivery systems for oral cancer treatment—current status and future perspectives. Pharmaceutics 11, 302. 10.3390/pharmaceutics11070302 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar‐ad V, Pribitkin E and Tuluc M (2014) Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 41, 217–234. [DOI] [PubMed] [Google Scholar]
- 7. Anneroth G, Batsakis J and Luna M (1987) Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 95, 229–249. [DOI] [PubMed] [Google Scholar]
- 8. Bryne M, Boysen M, Alfsen CG, Abeler VM, Sudbø J, Nesland JM, Kristensen GB, Piffko J and Bankfalvi A (1998) The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res 18, 4757–4764. [PubMed] [Google Scholar]
- 9. Almangush A, Salo T, Hangstrom J and Leivo I (2014) Tumor budding in head and neck squamous cell carcinoma ‐ a systematic review. Histopathology 65, 587–594. 10.1111/his.12471 [DOI] [PubMed] [Google Scholar]
- 10. Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, Katsurada Y, Nakamura T, Mochizuki H et al. (2012) New criteria for histologic grading of colorectal cancer. Am J Surg Pathol 36, 193–201. 10.1097/pas.0b013e318235edee [DOI] [PubMed] [Google Scholar]
- 11. Sun Y, Liang F, Cao W, Wang K, He J, Wang H and Wang Y (2014) Prognostic value of poorly differentiated clusters in invasive breast cancer. World J Surg Oncol 12, 310. 10.1186/1477-7819-12-310 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Miyazaki M, Aoki M, Okado Y, Koga K, Hamasaki M, Kiyomi F, Sakata T, Nakagawa T and Nabeshima K (2019) Poorly differentiated clusters predict a poor prognosis for external auditory canal carcinoma. Head Neck Pathol 13, 198–207. 10.1007/s12105-018-0939-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Tong WW, Tong GH and Liu Y (2018) Cancer stem cells and hypoxia‐inducible factors (Review). Int J Oncol 53, 469–476. [DOI] [PubMed] [Google Scholar]
- 14. Baillie R, Tan ST and Itinteang T (2017) Cancer stem cells in oral cavity squamous cell carcinoma: a review. Front Oncol 7, 112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Chen X, Guan H, Liu XD, Xie DF, Wang Y, Ma T, Huang B and Zhou PK (2018) p53 positively regulates the expression of cancer stem cell marker CD133 in HCT116 colon cancer cells. Oncol Lett 16, 431–438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Kamal AF, Pranatha DY, Sugito W, Rahman F, Susanto S, Mariya S and Chen WM (2018) Isolation, culture and characterization of cancer stem cells from primary osteosarcoma. Open Stem Cell J 5, 1–13. [Google Scholar]
- 17. Major AG, Pitty LP and Farah CS (2013) Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int 2013, 319489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Schenke‐Layland K, Nsair A, Van Handel B, Angelis E, Gluck JM, Votteler M, Goldhaber JI, Mikkola HK, Kahn M and Maclellan WR (2011) Recapitulation of the embryonic cardiovascular progenitor cell niche. Biomaterials 32, 2748–2756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Berard M and Tough DF (2002) Qualitative differences between naive and memory T cells. Immunology 106, 127–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Naher L, Kiyoshima T, Kobayashi I, Wada H, Nagata K, Fujiwara H, Ookuma YF, Ozeki S, Nakamura S and Sakai H (2012) STAT3 signal transduction through interleukin‐22 in oral squamous cell carcinoma. Int J Oncol 41, 1577–1586. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Alt E, Yan Y, Gehmert S, Song YH, Altman A, Gehmert S, Vykoukal D and Bai X (2011) Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony‐forming potential. Biol Cell 103, 197–208. [DOI] [PubMed] [Google Scholar]
- 22. Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Baugh EH, Ke H, Levine AJ, Bonneau RA and Chan CS (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25, 154–160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Meyer SN, Galván JA, Zahnd S, Sokol L, Dawson H, Lugli A and Zlobec I (2019) Co‐expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer‐associated stroma. Human Pathol 87, 18–27. [DOI] [PubMed] [Google Scholar]
- 25. Liu PF, Kang BH, Wu YM, Sun JH, Yen LM, Fu TY, Lin YC, Liou HH, Lin YS, Sie HC et al. (2017) Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial‐mesenchymal transition‐related proteins. PLoS One 12, e0178581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Tadokoro A, Kanaji N, Liu D, Yokomise H, Haba R, Ishii T, Takagi T, Watanabe N, Kita N, Kadowaki N et al. (2016) Vimentin regulates invasiveness and is a poor prognostic marker in non‐small cell lung cancer. Anticancer Res 36 1545–1551. [PubMed] [Google Scholar]
- 27. Fishman WH, Inglis NR, Green S, Anstiss CL, Gosh NK, Reif AE, Rustigian R, Krant MJ and Stolbach LL (1968) Immunology and biochemistry of Regan isoenzyme of alkaline phosphatase in human cancer. Nature 219, 697–699. [DOI] [PubMed] [Google Scholar]
- 28. Noguchi K, Eguchi H, Konno M, Kawamoto K, Nishida N, Koseki J, Wada H, Marubashi S, Nagano H, Doki Y et al. (2015) Susceptibility of pancreatic cancer stem cells to reprogramming. Cancer Sci 106, 1182–1187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. O'Connor MD, Kardel MD, Iosfina I, Youssef D, Lu M, Li MM, Vercauteren S, Nagy A and Eaves CJ (2008) Alkaline phosphatase‐positive colony formation is a sensitive, specific, and quantitative indicator of undifferentiated human embryonic stem cells. Stem Cells 26, 1109–1116. [DOI] [PubMed] [Google Scholar]
- 30. Al‐Mudamgha ZA, Rassam MB, Al‐Salihi AR and Al‐Sammeraie FT (1997) Alkaline phosphatase of cancerous larynx tissue in comparison with the placental enzyme. Biochem Histochem Stud Acta Oncol 36, 213–218. [DOI] [PubMed] [Google Scholar]
- 31. Plaks V, Kong N and Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16, 225–238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Zhou J, Tao D, Xu Q, Gao Z and Tang D (2015) Expression of E‐cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol 8, 3150–3154. [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Fig. S1. P53 sequencing analysis in human‐derived SCC. Somatic mutation in exon 7 of TP53 (TP53G245S), visualized using the Integrated Genomic Viewer (IGV). The sequencing coverage, reads, and altered bases in skin tissue (top), donor tumor tissues (middle), and the cell line (bottom) are shown.
Table S1. Short tandem repeat (STR) profiles.
Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.